Entities / Company
Recursion (United States).
company in Salt Lake City, United States
- Reports this week
- 1
- Active events
- 1
- Connections
- 82
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
-
A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.Some support1 report2 developments inside
-
Recursion (United States) disclosed insider trading via required filings with the SEC on June 6, 2026.Some support3 reports
-
Trump's pledge to unleash oil and gas benefits stocks, involving Willis Towers Watson.Some support8 reports
One to three months ago
-
MarketBeat is providing analyst ratings for Recursion Pharmaceuticals.Some support2 reports
-
Recursion Pharmaceuticals is listed on Nasdaq, and BioCardia, Inc. is a company developing therapeutics in the United States.Some support1 report
-
Goodman and Recursion have formed a collaboration that is generating payments and undergoing regulatory review for drug development.Some support1 report
-
A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.Some support1 report1 development inside
-
Hoffmann-La Roche and Recursion utilized an AI platform to identify novel targets, including an advanced neuroscience target, for early discovery.Some support1 report
Gone quiet
No new reports in 90+ days-
Recursion (United States) was included in Russell Value/Small-Cap Benchmarks, expanding its investor base and liquidity.Some support1 report
-
DMD develops therapeutics targeting muscle tissue through strategic collaborations involving Roche, Recursion, and Dyne Therapeutics.Some support1 report
-
Sanofi provided a $7 million milestone payment related to an agreement for upgrading a therapeutic development platform.Well supported4 reports1 development inside
-
Recursion is collaborating with the FDA on the drug candidate REC-4881.Some support2 reports
-
Recursion (United States) disclosed a sale transaction via filings with the SEC on June 5, 2026, while its stock traded on NASDAQ.Some support1 report
-
Morgan Stanley initiated coverage and assigned ratings to Recursion Pharmaceuticals, Absci, and Schrodinger, while Recursion maintained partnerships with Sanofi and Bayer.Some support3 reports
-
Recursion Pharmaceuticals and Organon & Co. both reported positive Earnings ESP on July 22, 2025.Some support1 report
-
Recursion Pharmaceuticals has gained backing from a technology giant, and Peter Ray has joined the company as a senior director.Some support2 reports
-
AI technology is central to the operations of Recursion Pharmaceuticals.Some support5 reports1 development inside
-
Recursion Pharmaceuticals, in collaboration with academic institutions, achieved a major technical milestone by successfully training and open-sourcing the AlphaFold3 model, Boltz-2, using BioHive-2 data.Speculative1 report
-
Recursion Pharmaceuticals filed documents with the SEC regarding CEO stock sales, while Morgan Stanley cut the price target for the company.Well supported3 reports1 development inside
-
Recursion Pharmaceuticals and Biodexa Pharmaceuticals are developing treatments for FAP, with Biodexa in Phase 3 and Recursion in Phase 1b/2.Some support1 report
-
Recursion Pharmaceuticals benefits from Trump-era tariffs, reiterated Buy rating from Needham.Some support1 report
-
Recursion Pharmaceuticals experienced a decline on June 21, 2025, which lagged the losses of the S&P 500. The company was also placed into an industry group.Speculative1 report
-
Recursion Pharmaceuticals stock outperformed the S&P 500 in a trading session on July 18, 2025, while the broader medical sector was experiencing losses.Some support1 report
-
Recursion Pharmaceuticals, Merck KGaA, and Tempus expanded collaborations to leverage multimodal datasets and launch AI models for drug discovery.Some support1 report
-
Recursion Pharmaceuticals is utilizing an NVIDIA supercomputer for model training, leading to AlphaFold3 achieving a breakthrough with its Boltz-2 model.Speculative1 report
-
Nvidia has acquired equity positions in Recursion Pharmaceuticals, Nebius Group, and WeRide.Some support2 reports
-
Recursion Pharmaceuticals acquired Rallybio's joint venture stake.Some support5 reports
-
Recursion Pharmaceuticals and Anika Therapeutics were noted to be operating in the Medical - Biomedical and Genetics industry.Some support1 report
-
Recursion Pharmaceuticals' strategic updates prompted a price target revision by Morgan Stanley on June 26, 2025.Speculative1 report
-
CEO Christopher Gibson sold company shares of Recursion Pharmaceuticals.Some support1 report
-
Recursion Pharmaceuticals underperformed relative to the S&P 500 on August 22, 2025.Some support2 reports
-
Recursion announces its global presence, including offices in Montréal, London, and Oxford, and plans a live stream on LinkedIn.Some support2 reports
-
Rallybio and Recursion initiated preclinical studies for the compound REV102.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Recursion (United States) this week
News at the entities that move Recursion (United States) most-
Nvidia StructuralMark Zuckerberg holds a 13.5% stake in Meta, and S&P Global is tracking Meta's ownership status while the company competes in the AI market.Moves Recursion (United States)
-
BAYER OperationalSean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Moves Recursion (United States)
-
FDA StructuralFDA rated generic equivalent to brand Climara Pro.Moves Recursion (United States)
-
Morgan Stanley OperationalRBC, Keefe, Bruyette & Woods, and Morgan Stanley issued rating and price target updates for D.R. Horton, Inc.Moves Recursion (United States)
-
SEC StructuralKahn Brothers Group Inc. purchased a stake in First National Bank Alaska, which operates in Alaska and files reports with the SEC.Moves Recursion (United States)
-
Khan StructuralWest Yorkshire Police launched confiscation proceedings against Khan in Dewsbury, involving Arif.Moves Recursion (United States)
Connections
The 20 strongest of 82, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Nvidia Structural
Nvidia provides critical investment and computational resources, enabling Recursion to develop specialized AI and OS solutions.
-
Hoffmann-La Roche Structural
The relationship is a critical, ongoing strategic partnership focused on joint drug discovery, generating mutual revenue and candidates.
-
BAYER Operational
Bayer and Recursion maintain a strategic partnership focused on joint AI development and therapeutic candidates, generating mutual revenue from collaborations.
-
FDA Structural
The FDA provides necessary regulatory oversight and approval pathways for Recursion's drug development activities.
-
Nasdaq Structural
Recursion is a company publicly listed on the Nasdaq exchange.
-
Morgan Stanley Operational
Morgan Stanley provides financial analysis, ratings, and price target revisions for Recursion.
-
SEC Structural
Recursion is subject to mandatory regulatory oversight by the SEC, requiring disclosure of transactions and trading activities.
-
Khan Structural
Khan serves as the CEO and President of Recursion.
Show all 20 connections
-
Merck Operational
Recursion and Merck maintain an active strategic partnership focused on developing oncology and immunology candidates, leading to revenue for Recursion.
-
CGA Transactional
Recursion plans to present its data at the CGA-IGC conference/event.
-
Sanofi Operational
The two companies are engaged in a critical strategic alliance focused on automated biological research and shared development goals.
-
Milton Park Shared context
Recursion's automated labs are located in Milton Park, Oxfordshire.
-
London Shared context
Recursion maintains operational offices in the global hub of London.
-
MarketBeat Mentioned together
MarketBeat provides analyst ratings and financial tracking for Recursion Pharmaceuticals.
-
China Mentioned together
Recursion is noted for tracking and emphasizing the role of China's drug innovation and scientific development.
-
Goodman Transactional
Goodman and Recursion are engaged in a collaboration that generates upfront and milestone payments.
-
Montréal Shared context
Recursion maintains a physical office presence in Montréal.
-
Utah Shared context
Recursion is headquartered in Utah.
-
Ark Invest Transactional
Ark Invest executed a transaction by purchasing shares of Recursion Pharmaceuticals.
-
Oxford Shared context
Recursion maintains physical offices within the Oxford area.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
2 eventsJuly 2026
3 events- A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.
- Recursion (United States) was included in Russell Value/Small-Cap Benchmarks, expanding its investor base and liquidity.
- DMD develops therapeutics targeting muscle tissue through strategic collaborations involving Roche, Recursion, and Dyne Therapeutics.
Show 1 earlier month
June 2026
27 events- Recursion Pharmaceuticals announced strategic alliances with Bayer, Sanofi, Roche, Merck, and Genentech.
- A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.
- Recursion (United States) disclosed insider trading via required filings with the SEC on June 6, 2026.
- Trump's pledge to unleash oil and gas benefits stocks, involving Willis Towers Watson.
- Sanofi provided a $7 million milestone payment related to an agreement for upgrading a therapeutic development platform.
- Recursion is collaborating with the FDA on the drug candidate REC-4881.
- Recursion (United States) disclosed a sale transaction via filings with the SEC on June 5, 2026, while its stock traded on NASDAQ.
- Morgan Stanley initiated coverage and assigned ratings to Recursion Pharmaceuticals, Absci, and Schrodinger, while Recursion maintained partnerships with Sanofi and Bayer.
- Recursion Pharmaceuticals and Organon & Co. both reported positive Earnings ESP on July 22, 2025.
- Recursion Pharmaceuticals has gained backing from a technology giant, and Peter Ray has joined the company as a senior director.
- AI technology is central to the operations of Recursion Pharmaceuticals.
- Recursion Pharmaceuticals, in collaboration with academic institutions, achieved a major technical milestone by successfully training and open-sourcing the AlphaFold3 model, Boltz-2, using BioHive-2 data.
- Recursion Pharmaceuticals filed documents with the SEC regarding CEO stock sales, while Morgan Stanley cut the price target for the company.
- Recursion Pharmaceuticals and Biodexa Pharmaceuticals are developing treatments for FAP, with Biodexa in Phase 3 and Recursion in Phase 1b/2.
- Recursion Pharmaceuticals benefits from Trump-era tariffs, reiterated Buy rating from Needham.
- Recursion Pharmaceuticals experienced a decline on June 21, 2025, which lagged the losses of the S&P 500. The company was also placed into an industry group.
- Recursion Pharmaceuticals stock outperformed the S&P 500 in a trading session on July 18, 2025, while the broader medical sector was experiencing losses.
- Recursion Pharmaceuticals, Merck KGaA, and Tempus expanded collaborations to leverage multimodal datasets and launch AI models for drug discovery.
- Recursion Pharmaceuticals is utilizing an NVIDIA supercomputer for model training, leading to AlphaFold3 achieving a breakthrough with its Boltz-2 model.
- Nvidia has acquired equity positions in Recursion Pharmaceuticals, Nebius Group, and WeRide.
- Recursion Pharmaceuticals acquired Rallybio's joint venture stake.
- Recursion Pharmaceuticals and Anika Therapeutics were noted to be operating in the Medical - Biomedical and Genetics industry.
- Recursion Pharmaceuticals' strategic updates prompted a price target revision by Morgan Stanley on June 26, 2025.
- CEO Christopher Gibson sold company shares of Recursion Pharmaceuticals.
- Recursion Pharmaceuticals underperformed relative to the S&P 500 on August 22, 2025.
- Recursion announces its global presence, including offices in Montréal, London, and Oxford, and plans a live stream on LinkedIn.
- Rallybio and Recursion initiated preclinical studies for the compound REV102.